NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items.